Cite
Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China
MLA
Cao Jing, et al. “Treatment Persistence of Bictegravir/Emtricitabine/Tenofovir Alafenamide and Efavirenz + Lamivudine + Tenofovir Disoproxil among HIV-1 Patients Newly Starting Treatment in Hunan Province in China.” BMC Infectious Diseases, vol. 23, no. 1, June 2023, pp. 1–7. EBSCOhost, https://doi.org/10.1186/s12879-023-08359-w.
APA
Cao Jing, Tang Wei, Wang Ning, Zheng Fang, Xiao Gang, Wang Xingzhi, Zhou Guoqiang, & Wang Min. (2023). Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China. BMC Infectious Diseases, 23(1), 1–7. https://doi.org/10.1186/s12879-023-08359-w
Chicago
Cao Jing, Tang Wei, Wang Ning, Zheng Fang, Xiao Gang, Wang Xingzhi, Zhou Guoqiang, and Wang Min. 2023. “Treatment Persistence of Bictegravir/Emtricitabine/Tenofovir Alafenamide and Efavirenz + Lamivudine + Tenofovir Disoproxil among HIV-1 Patients Newly Starting Treatment in Hunan Province in China.” BMC Infectious Diseases 23 (1): 1–7. doi:10.1186/s12879-023-08359-w.